HUTCHMED says savolitinib plus AstraZeneca’s Tagrisso lifts PFS and OS in Phase III lung cancer trial

• HUTCHMED reported positive top-line Phase III SAFFRON results for savolitinib with osimertinib in MET-driven EGFR-mutated NSCLC progressing on osimertinib.
• The combination improved progression-free survival and overall survival versus platinum-based doublet chemotherapy, supporting a biomarker-directed oral option in this setting.
• Data will be presented at a future medical meeting and submitted to global regulators, setting up potential registrations outside China.
• Safety matched known profiles for each drug with no new safety signals, reducing execution risk for broader commercial rollout.
• The regimen is already marketed in China for EGFR-mutated NSCLC with MET amplification following EGFR-TKI progression, based on the SACHI Phase III trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608162000PRIMZONEFULLFEED9810883) on August 17, 2026, and is solely responsible for the information contained therein.